Modalis Therapeutics Corporation (4883.T)
JPY 75.0
(-1.32%)
JPY 75.0
(-1.32%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.37 Billion JPY | 12.69% |
| 2022 | 2.1 Billion JPY | 69.58% |
| 2021 | 1.24 Billion JPY | 67.56% |
| 2020 | 740.35 Million JPY | 48.37% |
| 2019 | 499 Million JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 490.08 Million JPY | -35.62% |
| 2024 Q2 | 348.86 Million JPY | -28.81% |
| 2023 Q1 | 514.44 Million JPY | -13.06% |
| 2023 Q4 | 761.23 Million JPY | 34.82% |
| 2023 Q3 | 564.64 Million JPY | 6.47% |
| 2023 FY | 2.37 Billion JPY | 12.69% |
| 2023 Q2 | 530.34 Million JPY | 3.09% |
| 2022 Q3 | 537.72 Million JPY | 0.0% |
| 2022 FY | 2.1 Billion JPY | 69.58% |
| 2022 Q4 | 591.69 Million JPY | 10.04% |
| 2021 FY | 1.24 Billion JPY | 67.56% |
| 2020 FY | 740.35 Million JPY | 48.37% |
| 2019 FY | 499 Million JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 43.63 Billion JPY | 94.568% |
| Takeda Pharmaceutical Company Limited | 2618.18 Billion JPY | 99.909% |
| Sumitomo Pharma Co., Ltd. | 542.17 Billion JPY | 99.563% |
| Shionogi & Co., Ltd. | 197.62 Billion JPY | 98.8% |
| Wakamoto Pharmaceutical Co.,Ltd. | 3.73 Billion JPY | 36.551% |
| Nippon Shinyaku Co., Ltd. | 65.63 Billion JPY | 96.388% |
| Kaken Pharmaceutical Co., Ltd. | 29.02 Billion JPY | 91.833% |
| Eisai Co., Ltd. | 533.01 Billion JPY | 99.555% |
| Morishita Jintan Co., Ltd. | 5.28 Billion JPY | 55.118% |
| Hisamitsu Pharmaceutical Co., Inc. | 65.8 Billion JPY | 96.397% |
| Mochida Pharmaceutical Co., Ltd. | 46.26 Billion JPY | 94.876% |
| Fuso Pharmaceutical Industries,Ltd. | 11.55 Billion JPY | 79.48% |
| Nippon Chemiphar Co., Ltd. | 8.23 Billion JPY | 71.202% |
| Tsumura & Co. | 48.8 Billion JPY | 95.142% |
| Kissei Pharmaceutical Co., Ltd. | 33.32 Billion JPY | 92.886% |
| Torii Pharmaceutical Co., Ltd. | 19.53 Billion JPY | 87.866% |
| Towa Pharmaceutical Co., Ltd. | 63.73 Billion JPY | 96.28% |
| Fuji Pharma Co., Ltd. | 12.65 Billion JPY | 81.27% |
| Zeria Pharmaceutical Co., Ltd. | 40.46 Billion JPY | 94.141% |
| KYORIN Holdings, Inc. | 45.39 Billion JPY | 94.778% |
| Taiko Pharmaceutical Co.,Ltd. | 4.15 Billion JPY | 42.972% |
| Daito Pharmaceutical Co.,Ltd. | 5.94 Billion JPY | 60.123% |
| SymBio Pharmaceuticals Limited | 5.22 Billion JPY | 54.608% |
| MedRx Co., Ltd | 959 Million JPY | -147.202% |
| Mizuho Medy Co.,Ltd. | 2.87 Billion JPY | 17.506% |
| Solasia Pharma K.K. | 1.47 Billion JPY | -60.614% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 24.16 Billion JPY | 90.19% |
| Sawai Group Holdings Co., Ltd. | 35.43 Billion JPY | 93.309% |
| Cyfuse Biomedical K.K. | 735.18 Million JPY | -222.46% |
| Toho Holdings Co., Ltd. | 99.81 Billion JPY | 97.625% |
| Koa Shoji Holdings Co.,Ltd. | 2.25 Billion JPY | -5.023% |